-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Upgrades WAVE Life Sciences to Outperform, Raises Price Target to $27

Benzinga·12/09/2025 12:06:13
Listen to the news
RBC Capital analyst Luca Issi upgrades WAVE Life Sciences (NASDAQ:WVE) from Sector Perform to Outperform and raises the price target from $9 to $27.